Indications to Treat Cutaneous T cell lymphoma
Cutaneous T-cell lymphoma (CTCL) is rare and difficult to recognize malignant tumor of the lymphatic system. The disease is caused by an uncontrolled increase in T lymphocytes located in the lymphatic system of the skin and often mistaken with psoriasis or eczema.
Factors regulating CTCL pathogenesis are still largely unknown, but STAT3 protein, a messenger and transcription factor responsible for CTCL cell proliferation and survival, has been identified as the primary target. STAT3 is the molecular stimulus that triggers CTCL tumor development and tumor-induced immune tolerance.
By targeting the signaling pathway consisting of many factors mediated by p-STAT3, survival, the response rate can be improved and the time to relapse/progression in CTCL patients can be significantly extended.
WP1220 is the first pSTAT3-targeted drug used in monotherapy for patients with CTCL and giving the opportunity to be used in other skin cancers and diseases associated with STAT3.
WP1220 is already clinical trials in Poland.
Cutaneous T-cell lymphoma
Partners, Affiliations & License
MD Anderson, leading cancer research center in the world
Moleculin Biotech, Inc. – co-development partner
The expected market size is in excess of $1 billion.